Serial 98906925
Live / Applied — Second extension granted (statement of use) (as of 09 Sept 2026)
What this means for you
Not registered yet, but its 17 Dec 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98906925
- Mark type
- Design / logo
- Filed
- 17 Dec 2024
- Published for opposition
- 15 Jul 2025
- Attorney of record
- Karen Won
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations; pharmaceutical preparations for use in oncology; pharmaceutical for preventing, diagnosing, treating and managing cancer; pharmaceutical preparations for inhibiting pan-oncogenic RAS proteins; therapeutic agents, namely, RAS protein inhibitors
- Class 042 — Scientific and technological services: Research and development in the fields of pharmaceuticals, cancer therapies, and oncogenic RAS proteins; providing medical scientific research information in the fields of pharmaceuticals, cancer therapies, and oncogenic RAS proteins
Owner
- Kestrel Therapeutics Inc., Allston, MA, US
- Kestrel Therapeutics Inc., Allston, MA, US
Prosecution history
- 10 Sept 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Sept 2026 — SOU EXTENSION 2 GRANTED
- 09 Sept 2026 — SOU EXTENSION 2 FILED
- 09 Sept 2026 — SOU TEAS EXTENSION RECEIVED
- 24 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Feb 2026 — SOU EXTENSION 1 GRANTED
- 23 Feb 2026 — SOU EXTENSION 1 FILED
- 23 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 09 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Jul 2025 — PUBLISHED FOR OPPOSITION
- 09 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 03 Jun 2025 — ASSIGNED TO EXAMINER
- 26 May 2025 — NOTICE OF DESIGN SEARCH CODE E-MAILED